Goldman Sachs
NBIX icon

Goldman Sachs’s Neurocrine Biosciences NBIX Stock Holding History

Goldman Sachs’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Buy
13,700
+11,200
+448% +$1.49M ﹤0.01% 4630
2025
Q4 		$355K Hold
2,500
– – ﹤0.01% 5780
2025
Q3 		$351K Sell
2,500
-8,800
-78% -$1.19M ﹤0.01% 5687
2025
Q2 		$1.42M Buy
+11,300
New +$1.3M ﹤0.01% 4442
2022
Q1 		– Sell
-30,000
Closed -$2.56M – 6795
2021
Q4 		$2.56M Buy
+30,000
New +$2.76M ﹤0.01% 4033
2021
Q3 		– Sell
-140,000
Closed -$13.6M – 6415
2021
Q2 		$13.6M Hold
140,000
– – ﹤0.01% 2404
2021
Q1 		$13.6M Sell
140,000
-15,200
-10% -$1.59M ﹤0.01% 2281
2020
Q4 		$14.9M Buy
155,200
+89,900
+138% +$8.68M ﹤0.01% 2114
2020
Q3 		$6.28M Buy
65,300
+15,200
+30% +$1.76M ﹤0.01% 2722
2020
Q2 		$6.11M Sell
50,100
-10,000
-17% -$1.11M ﹤0.01% 2646
2020
Q1 		$5.2M Buy
60,100
+10,100
+20% +$988K ﹤0.01% 2603
2019
Q4 		$5.37M Buy
+50,000
New +$5.24M ﹤0.01% 2902
2016
Q2 		– Sell
-39,300
Closed -$1.55M – 7163
2016
Q1 		$1.55M Sell
39,300
-10,800
-22% -$429K ﹤0.01% 3708
2015
Q4 		$2.83M Sell
50,100
-36,100
-42% -$1.83M ﹤0.01% 3326
2015
Q3 		$3.43M Buy
86,200
+37,300
+76% +$1.8M ﹤0.01% 3236
2015
Q2 		$2.33M Sell
48,900
-100
-0.2% -$4.24K ﹤0.01% 3688
2015
Q1 		$1.95M Buy
+49,000
New +$1.75M ﹤0.01% 3809
2014
Q4 		– Sell
-131,700
Closed -$2.06M – 7245
2014
Q3 		$2.06M Buy
131,700
+39,300
+43% +$587K ﹤0.01% 3909
2014
Q2 		$1.37M Sell
92,400
-48,000
-34% -$677K ﹤0.01% 4392
2014
Q1 		$2.26M Buy
+140,400
New +$2.4M ﹤0.01% 3859

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's NBIX Position: Q1 2026 in Review

Goldman Sachs reduced its Neurocrine Biosciences (NBIX) stake by 4.2% in Q1 2026, selling an estimated $2.04M and leaving 349,179 shares worth $46M. The position accounts for 0.01% of the portfolio, ranked #1645.

Goldman Sachs first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q4 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Goldman Sachs held 349,179 shares of Neurocrine Biosciences worth $46M as of Q1 2026.
  • Goldman Sachs sold 15,356 Neurocrine Biosciences shares in Q1 2026, an estimated $2.04M.
  • Neurocrine Biosciences made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1645 holding.
  • Goldman Sachs first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Neurocrine Biosciences position peaked at $166M in Q4 2017.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.